Converting enzyme inhibitors in heart failure

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• The renin-angiotensin system (RAS) is activated in heart failure, correlating with disease severity and diuretic use.
• RAS activation contributes to hemodynamic derangement in heart failure patients.

Purpose of the Study:

• To evaluate the effects of Angiotensin Converting Enzyme (ACE) inhibitors on neurohormonal levels and circulatory dynamics in heart failure.
• To assess the impact of ACE inhibitors on renal function and electrolyte balance.
• To discuss potential hazards and future therapeutic trends of ACE inhibitor use in cardiac conditions.

Main Methods:

• Review of existing literature on ACE inhibitor therapy in heart failure.
• Analysis of changes in hormone levels (angiotensin II, aldosterone, noradrenaline, vasopressin, cortisol) and electrolytes (potassium, sodium).
• Evaluation of hemodynamic parameters, glomerular filtration rate, and organ blood flow.

Main Results:

• ACE inhibitors reduce angiotensin II and aldosterone, potentially lowering noradrenaline, vasopressin, and cortisol.
• Potassium retention is typical, with variable sodium balance depending on patient status and diuretic policy.
• Circulatory dynamics generally improve, preserving blood flow to the brain, myocardium, and kidneys.

Conclusions:

• ACE inhibitors offer significant benefits in managing heart failure by counteracting the activated renin-angiotensin system.
• Careful management can mitigate potential hazards associated with ACE inhibitor therapy.
• Future applications may include early-stage heart failure and post-myocardial infarction treatment.